Skip to content

Nintendo Wii Virtual Reality Application In Dementia

Nintendo Wii Virtual Reality Application In Older People With Alzheimer's Dementia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04819126
Enrollment
32
Registered
2021-03-26
Start date
2018-01-15
Completion date
2019-01-15
Last updated
2021-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Memory Disorders

Keywords

Alzheimer's Dementia, Muscle strength, Fall, Virtual reality

Brief summary

•This study was planned to investigate the effects of the Nintendo Wii virtual reality application on muscle strength and fall risk in individuals with AD. The aim of the present study is to investigate the effect of the virtual reality application on muscle strength and fall in individuals with Alzheimer' Dementia (AD).

Detailed description

Purpose: This study was planned to investigate the effects of the Nintendo Wii virtual reality application on muscle strength and fall risk in individuals with AD. Method: The study included a total of 32 volunteers between the ages of 65-80, with mild or moderate AD diagnosed. These individuals were divided into 2 groups as a training group and control group. The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes. Mini-Mental State Test, Knee Extension Muscle Strength, Timed Up and Go Test, Tinetti Falls Efficacy Scale results of individuals were recorded in the evaluation.

Interventions

OTHERNintendo Wii Virtual Reality Application

The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes.

Sponsors

Kırıkkale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
65 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* included volunteers between the ages of 65-80 with mild or moderate AD diagnosis, * who did not have any difficulty or problems in communicating, * who did not have any neurological diseases that disrupt balance and coordination such as a cerebrovascular event, Parkinson's disease, Multiple Sclerosis, and neurological disorder, * who obtained a score of 18 - 24 points in the Mini-Mental State Test (MMST)

Exclusion criteria

* Patients diagnosed with rapidly progressing dementia (infection, vascular, hematologic diseases), * Those who could not be contacted during the follow-up period or who did not participate in the training session, those who experienced cardiac and cerebrovascular events, endocrine disorders, fluid-electrolyte imbalance and infection, * Those with malignancy and those who received chemotherapy and radiotherapy that causes malignancy, delirium or depression and malignant sensory loss (those with the Semmes-Weinstein monofilament thickness of 4.56 and above), * Those with a lower or upper extremity amputation at any level

Design outcomes

Primary

MeasureTime frameDescription
Age :mean or median ageperiod of 6 weeksAge, Categorical: \>=65 years
Body Mass Indexperiod of 6 weeksBMI was recorded in kg/m\^2.
Sex/Genderperiod of 6 weeksSex: Female, Male

Secondary

MeasureTime frameDescription
The Mini-Mental State Test for Cognitive statusperiod of 6 weeksAccording to the MMST, 24-30 points were considered as normal cognitive levels, 18-23 points were considered as mild cognitive disorders, and 0-17 points were considered as severe cognitive disorders

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026